Contineum Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
The company is advancing two clinical-stage assets, PIPE-791 and PIPE-307, with a focus on pulmonary fibrosis and MDD. PIPE-791 differentiates through once-daily dosing, high receptor occupancy, and a strong safety profile, while PIPE-307 is partnered with J&J for rapid-onset MDD therapy. Key catalysts this year include PIPE-791 pain data, J&J’s MDD results, and BMS’s phase III readout.
Fiscal Year 2025
-
Significant clinical progress was made with four studies, including advancing PIPE-791 for IPF and chronic pain. PIPE-791 differentiates through high receptor occupancy and once-daily dosing, targeting a large unmet need in IPF. Key catalysts include pain study data and BMS’s phase three results.
-
Two clinical-stage assets target neuroscience and immunology, with PIPE-791 advancing in IPF and pain, and PIPE-307 in MS and MDD via a J&J partnership. Key data readouts are expected this year and next, with strong patent protection and cash runway through 2027.
-
The conference highlighted a robust clinical pipeline with near-term data catalysts for two key assets targeting IPF, MS, and depression. PIPE-791 and PIPE-307 are positioned for differentiation through optimized dosing, strong partnerships, and focus on unmet needs, with multiple clinical readouts expected in the next year.
-
The company is advancing two clinical-stage assets, PIPE-791 and PIPE-307, targeting significant unmet needs in IPF, MS, and chronic pain. A global phase 2 IPF study for PIPE-791 will launch in Q4, with key data readouts expected over the next year.
-
Recent advances in LPA1 antagonist programs address prior safety issues and optimize dosing, with key PET data for type 791 expected soon. The pipeline expands into MS and pain, while the muscarinic program progresses in MS and depression through a J&J partnership. Strong IP and funding support continued development.
-
The company is advancing a robust clinical pipeline in neuroscience and immunology, with seven studies planned for 2025 and key data readouts expected this year for MS and depression programs. LPA1-targeted therapies are progressing in MS, IPF, and pain, and funding is secured through 2027.
-
Multiple clinical studies are advancing in 2025, including PIPE-791 in IPF, MS, and pain, and PIPE-307 in MS and MDD, with key data readouts expected. PIPE-791 aims to improve on BMS’s LPA1 inhibitor, while PIPE-307 is partnered with J&J in a $1.1B+ collaboration.
Fiscal Year 2024
-
The company is advancing two clinical-stage assets targeting neuroscience and immunology, with major Phase II studies in MS, IPF, and depression set for 2025. A strong partnership with J&J and a $215M cash runway support seven clinical trials, with key data readouts expected next year.
-
The panel highlighted clinical progress and differentiation of two assets targeting neuroscience and immunology, with PIPE-791 advancing in IPF, progressive MS, and pain, and a selective M1 antagonist in phase 2 for MS and depression. Strong scientific rationale, robust study designs, and a solid cash runway support future development.
-
The conference detailed a robust clinical pipeline targeting neuroscience and fibrotic diseases, with PIPE-307 and PIPE-791 advancing through key trials and a major J&J partnership. Strong financials and patent protection support multiple milestones through 2027.
-
The company is advancing two internally developed clinical-stage assets: PIPE-791, a brain-penetrant LPA1 inhibitor for IPF and progressive MS, and PIPE-307, a selective M1 antagonist for remyelination and depression, with strong clinical validation and a major partnership with J&J. Cash reserves of nearly $220 million are expected to fund operations through 2027.
-
The company is advancing two clinical-stage assets: PIPE-791, a once-daily LPA1 inhibitor for progressive MS and IPF, and PIPE-307, a selective M1 antagonist for CNS disorders, both with strong preclinical and early clinical validation. Key upcoming milestones include PET study data and phase 2 trial initiations in 2025.